Document Detail


Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels.
MedLine Citation:
PMID:  11212279     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We have demonstrated that Apo-2 ligand (Apo-2L)/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces apoptosis of human prostate cancer PC-3, DU145, and LNCaP cells in a dose-dependent manner, with PC-3 cells displaying the greatest sensitivity to Apo-2L/TRAIL. Susceptibility of the prostate cancer cell types to Apo-2L/TRAIL-induced apoptosis did not appear to correlate with the levels of the Apo-2L/TRAIL receptors death receptor (DR) 4 (TRAIL receptor 1) or DR5 (TRAIL receptor 2), decoy receptor (DcR) 1 and DcR2, Flame-1, or the inhibitors of apoptosis proteins family of proteins. Apo-2L/TRAIL-induced apoptosis of PC-3 cells was associated with the processing of caspase-8, caspase-10, and the proapoptotic Bid protein, resulting in the cytosolic accumulation of cytochrome c as well as the processing of procaspase-9 and procaspase-3. Cotreatment with the caspase-8 inhibitor z-IETD-fmk or DR4:Fc significantly inhibited Apo-2L/TRAIL-induced apoptosis. Treatment with paclitaxel or taxotere increased DR4 and/or DR5 protein levels (up to 8-fold) without affecting the protein levels of DcR1 and DcR2, Apo-2L/TRAIL, Fas, or Fas ligand. Up-regulation of DR4 and DR5 was not preceded by the induction of their mRNA levels but was inhibited by cotreatment with cycloheximide. Importantly, sequential treatment of PC-3, DU145, and LNCaP cells with paclitaxel followed by Apo-2L/TRAIL induced significantly more apoptosis than Apo-2L/TRAIL treatment alone (P < 0.01). This was also associated with greater processing of procaspase-8 and Bid, as well as greater cytosolic accumulation of cytochrome c and the processing of caspase-3. These findings indicate that up-regulation of DR4 and DR5 protein levels by treatment with paclitaxel enhances subsequent Apo-2L/TRAIL-induced apoptosis of human prostate cancer cells.
Authors:
R Nimmanapalli; C L Perkins; M Orlando; E O'Bryan; D Nguyen; K N Bhalla
Related Documents :
15538719 - Truncated e-cadherin potentiates cell death in prostate epithelial cells.
10980599 - Autoamplification of apoptosis following ligation of cd95-l, trail and tnf-alpha.
19896469 - Ampk-independent down-regulation of cflip and sensitization to trail-induced apoptosis ...
19617819 - Genistein sensitizes human hepatocellular carcinoma cells to trail-mediated apoptosis b...
20097879 - Identification of a novel proapoptotic function of resveratrol in fat cells: sirt1-inde...
11420819 - Alternative functions for trail receptors in eosinophils and neutrophils.
21035309 - Zinc-suppressed inflammatory cytokines by induction of a20-mediated inhibition of nucle...
21295129 - In vitro anti-inflammatory and anti-cancer activities of cuscuta reflexa roxb.
7355989 - Immunology of the lower respiratory tract. serial morphologic changes in the lungs and ...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Cancer research     Volume:  61     ISSN:  0008-5472     ISO Abbreviation:  Cancer Res.     Publication Date:  2001 Jan 
Date Detail:
Created Date:  2001-02-09     Completed Date:  2001-02-22     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  2984705R     Medline TA:  Cancer Res     Country:  United States    
Other Details:
Languages:  eng     Pagination:  759-63     Citation Subset:  IM    
Affiliation:
Moffitt Cancer Center and Research Institute, University of South Florida, Tampa 33612, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Agents, Phytogenic / pharmacology
Apoptosis / drug effects*
Apoptosis Regulatory Proteins
Blotting, Western
Dose-Response Relationship, Drug
Drug Synergism
Humans
Male
Membrane Glycoproteins / pharmacology*
Paclitaxel / pharmacology*
Prostatic Neoplasms / metabolism,  pathology,  prevention & control*
Receptors, TNF-Related Apoptosis-Inducing Ligand
Receptors, Tumor Necrosis Factor / drug effects*,  metabolism
TNF-Related Apoptosis-Inducing Ligand
Tumor Cells, Cultured
Tumor Necrosis Factor-alpha / pharmacology*
Up-Regulation / drug effects
Chemical
Reg. No./Substance:
0/Antineoplastic Agents, Phytogenic; 0/Apoptosis Regulatory Proteins; 0/Membrane Glycoproteins; 0/Receptors, TNF-Related Apoptosis-Inducing Ligand; 0/Receptors, Tumor Necrosis Factor; 0/TNF-Related Apoptosis-Inducing Ligand; 0/TNFRSF10A protein, human; 0/TNFRSF10B protein, human; 0/TNFSF10 protein, human; 0/Tumor Necrosis Factor-alpha; 33069-62-4/Paclitaxel

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modu...
Next Document:  A truncated human xeroderma pigmentosum complementation group A protein expressed from an adenovirus...